# ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

> **NCT07542717** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 41 (estimated)

## Conditions studied

- Recurrent or Metastatic Cervical Cancer

## Interventions

- **DRUG:** Treatment

## Key facts

- **NCT ID:** NCT07542717
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2028-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07542717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07542717, "ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07542717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*